'I'm allergic to winter - I can't even walk down the freezer aisle in the supermarket'

EXCLUSIVE: Kirsten Evans suffers a severe reaction to cold exposure that makes every winter a living nightmare ...

Here’s what to know about ticks as you head outdoors in Florida this winter

Winter in Florida means more time outdoors, and possibly more exposure to tick-borne diseases. But the news isn’t all bad: ...

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

U.S. FDA Approves PADCEV(R) plus Keytruda(R) for Certain Patients with Bladder Cancer

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Could Your Manicure Be To Blame For Your Face Rash? Possibly—Here's Why.

In a recent Instagram post, one prominent New York City dermatologist exposed a common culprit behind skin rashes: gel ...
FMIBlog

Drug Eruptions Treatment Market Size and Share Forecast Outlook 2025 to 2035

The Drug Eruptions Treatment Market is projected to experience significant expansion between 2025 and 2035, fueled by the ...

Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

The presentations will include new findings on mogamulizumab's therapeutic benefit, safety, and pharmacodynamic profile, and insight into alternative dosing strategies, real-world treatment patterns, ...
AARP

5 Types of Allergies That Can Become More Common With Age

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Learn smart ways to save + get daily chances to win gift cards ...
BioSpace

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

"Choosing the first treatment for EGFR-mutated NSCLC is one of the most important decisions we make. It can influence how the disease progresses over time," said Joshua Bauml, M.D., Vice President, ...
Morningstar

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line ...

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...